Drug Trial Radar · NCT07603557
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Aug 31, 2026
Primary completion
May 6, 2030
Study completion May 6, 2030
Sponsor
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- May 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and autoimmune hemolytic anemia (AIHA).
Conditions
- Chronic Immune Thrombocytopenia
- Autoimmune Hemolytic Anemia
Interventions
BMS-986353Biological
Specified dose of specified days
Fludarabine PhosphateDrug
Specified dose of specified days
CyclophosphamideDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1 Part A: Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to approximately Month 36
- Cohort 1 Part A: Number of participants with serious AEs (SAEs)Time frame: Up to approximately Month 36
- Cohort 1 Part A: Number of participants with AEs of special interest (AESI)Time frame: Up to approximately Month 36
- Cohort 1 Part A: Number of participants with clinically significant laboratory abnormalitiesTime frame: Up to approximately Month 36
- Cohort 1 Part B: Hematologic Complete Response (CR)Time frame: Up to approximately Month 6
Locations
8 sites in 4 countries. Site status is shown where the registry gives one.
Local Institution - 101
Boston, Massachusetts
Local Institution - 103
Houston, Texas
Local Institution - 102
Seattle, Washington
Local Institution - 201
Odense, Denmark
Local Institution - 302
Erlangen, Germany
Local Institution - 301
Magdeburg, Saxony-Anhalt, Germany
Local Institution - 402
Sheffield, United Kingdom
Local Institution - 401
London, Greater London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.